Stock comparison
Eli Lilly
Thermo Fisher Scientific
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$981.2B
Sector
Healthcare
TMO
Thermo Fisher Scientific
Market cap
$167B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | TMO | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 52C | LLY |
| Benjamin Graham | 86A | 72B | LLY |
| Philip Fisher | 86A | 39D | LLY |
| Peter Lynch | 74B | 28F | LLY |
| Joel Greenblatt | 78C | 48D | LLY |
| Charlie Munger | 85A | 51D | LLY |
| Terry Smith | 77C | 44D | LLY |
Side-by-side metrics
| Metric | LLY | TMO |
|---|---|---|
| Market cap | $981.2B | $167B |
| P/E (TTM) | 36.6x | 23.8x |
| EV/EBIT | 34.1x | 25.0x |
| ROIC (TTM) | 32.06% | 7.33% |
| Gross margin | 83.51% | 39.41% |
| Net margin | 34.98% | 15.18% |
| Revenue CAGR 5y | 23.17% | 3.25% |
| EPS CAGR 5y | 40.81% | -2.43% |
| Debt / Equity | 1.4x | 0.8x |
| Dividend yield | 0.62% | 0.4% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- EPS CAGR 5y40.81%vs -2.43%+106%
- Revenue CAGR 5y23.17%vs 3.25%+86%
- Market cap$981.2Bvs $167B+83%
- ROIC (TTM)32.06%vs 7.33%+77%
TMO leads on
- Debt / Equity0.8xvs 1.4x+40%
- P/E (TTM)23.8xvs 36.6x+35%
- EV/EBIT25.0xvs 34.1x+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.